Propel Bio Management, LLC Athira Pharma, Inc. Transaction History
Propel Bio Management, LLC
- $154 Billion
- Q2 2024
A detailed history of Propel Bio Management, LLC transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Propel Bio Management, LLC holds 1,492,792 shares of ATHA stock, worth $641,900. This represents 2.57% of its overall portfolio holdings.
Number of Shares
1,492,792
Previous 1,492,792
-0.0%
Holding current value
$641,900
Previous $4.09 Billion
3.28%
% of portfolio
2.57%
Previous 2.38%
Shares
1 transactions
Others Institutions Holding ATHA
# of Institutions
75Shares Held
23.1MCall Options Held
73.4KPut Options Held
97.8K-
Perceptive Advisors LLC New York, NY5.4MShares$2.32 Million0.41% of portfolio
-
Baker Bros. Advisors LP New York, NY3.15MShares$1.36 Million0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.63MShares$702,8060.0% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$641,9000.29% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.3MShares$557,3350.02% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $16.3M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...